Polyneuropathy in diabetes mellitus: theory and practice
AbstractDiabetic polyneuropathy is a common complication of type 2 diabetes mellitus. It is a cause of decreasing of patient’s quality of life and a case of their disability. Polyneuropathy is an independent mortality risk factor in diabetes mellitus. Currently, methods of screening and objective assessment of neurological symptoms in diabetic polyneuropathy have been identified, as well as treatment approaches. Pathogenetic therapy with thioctic acid has repeatedly proven its effectiveness, while the doses and duration of such treatment have been approved. An important aspect in the management of patients with diabetes mellitus is to assess the risk of developing a deficiency or insufficiency of vitamin B 12, since this condition also contributes to the neurological symptom complex. Both diabetic and B 12-deficient polyneuropathy are curable conditions, which means a high probability of obtaining a good clinical result against the background of adequate doses and duration of therapy. The article presents 3 clinical examples confirming these theses.
Keywords:diabetic polyneuropathy; therapy; thioctic acid; clinic cases; vitamin B12 deficiency
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Suponeva N.A., Bedeneu N.V., Moysak G.I., Asadullaeva P.M., Nenashova Yu.N., Popryadukhina K.V., Egorenkova E.V., Kuralev D.V., Al’ Dzhayusi T.V., Oytsev A.V., Kozoderova E.V., Khybyrtova A.D., Kryachkov A.V. Polyneuropathy in diabetes mellitus: theory and practice. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2024; 13 (1): 96–103. DOI: https://doi.org/10.33029/2304-9529-2024-13-1-96-103 (in Russian)
References
1. Sadyrin A.V., Karpova M.I., Dolganov M.V. Diabetic polyneuropathy: issues of pathogenesis and treatment options. RMZh [Russian Medical Journal]. 2016; (1): 47–50. (in Russian)
2. Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43 (4): 817–24. DOI: https://doi.org/10.1212/wnl.43.4.817 PMID: 8469345.
3. Lu Y., Xing P., Cai X., Luo D., Li R., Lloyd C., et al. Prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: estimates of the INTERPRET-DD study. Front Public Health. 2020; 8: 534372. DOI: https://doi.org/10.3389/fpubh.2020.534372 PMID: 33194943; PMCID: PMC7606804.
4. Hicks C.W., Wang D., Matsushita K., Windham B.G., Selvin E. Peripheral neuropathy and all-cause and cardiovascular mortality in U.S. adults: a prospective cohort study. Ann Intern Med. 2021; 174 (2): 167–74. DOI: https://doi.org/10.7326/M20-1340 PMID: 33284680; PMCID: PMC7932559.
5. URL: https://painmed.ru/wp-content/uploads/2020/03/DN4.pdf
6. URL: https://painmed.ru/wp-content/uploads/2020/03/PainDetect.pdf
7. Zhao N., Xu J., Zhou Q., Li X., Chen J., Zhou J., et al. Application of the Ipswich Touch Test for diabetic peripheral neuropathy screening: a systematic review and meta-analysis. BMJ Open. 2021; 11 (10): e046966. DOI: https://doi.org/10.1136/bmjopen-2020-046966 PMID: 34607858; PMCID: PMC8491285.
8. Moghtaderi A., Bakhshipour A., Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006; 108 (5): 477–81. DOI: https://doi.org/10.1016/j.clineuro.2005.08.003 PMID: 16150538.
9. Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol. 1999; 41 (suppl 1): 8–13. DOI: https://doi.org/10.1159/000052074 PMID: 10023123.
10. Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995; 38 (12): 1425–33. DOI: https://doi.org/10.1007/BF00400603 PMID: 8786016.
11. Gur’eva I.V. Diabetic sensorimotor polyneuropathy – a cholistic approach. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (4): 26–47. DOI: https://doi.org/10.33029/2304-9529-2022-11-4-26-47 (in Russian)
12. Kakarlapudi Y., Kondabolu S., Tehseen Z., et al. Effect of metformin on vitamin B12 deficiency in patients with type 2 diabetes mellitus and factors associated with it: a meta-analysis. Cureus. 2022; 14 (12): e32277. DOI: https://doi.org/10.7759/cureus.32277
13. Bolieva L.Z., Bolotina L.V., Galstyan G.R., Drapkina O.M., Ekusheva E.V., Kaprin A.D., et al. Resolution of the Expert Council «Insufficiency/deficiency of vitamin B12 in clinical practice». Therapy. 2023; 9 (1): 116–21. DOI: https://doi.org/10.18565/therapy.2023.1.116-121 (in Russian)
14. Agathos E., Tentolouris A., Eleftheriadou I., et al. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res. 2018; 46 (5): 1779–90. DOI: https://doi.org/10.1177/0300060518756540
15. Ametov A.S., Barinov A., Dyck P.J., et al. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the Sydney trial. Diabetes Care. 2003; 26 (3): 770–6. DOI: https://doi.org/10.2337/diacare.26.3.770
16. Garcia-Alcala H., Santos Vichido C.I., Islas Macedo S., et al. Treatment with α-lipoic acid over 16 weeks in type 2 diabetic patients with symptomatic polyneuropathy who responded to initial 4-week high-dose loading. J Diabetes Res. 2015; 2015: 189857. DOI: https://doi.org/10.1155/2015/189857
17. Mijnhout G.S., Kollen B.J., Alkhalaf A., et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012; 2012: 456279. DOI: https://doi.org/10.1155/2012/456279
18. Ruhnau K.J., Meissner H.P., Finn J.R., et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alphalipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999; 16 (12): 1040–3. DOI: https://doi.org/10.1046/j.1464-5491.1999.00190.x
19. Ziegler D., Ametov A., Barinov A., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006; 29 (11): 2365–70. DOI: https://doi.org/10.2337/dc06-1216
20. Ziegler D., Low P.A., Freeman R., et al. Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial. J Diabetes Complications. 2016; 30 (2): 350–6. DOI: https://doi.org/10.1016/j.jdiacomp.2015.10.018
21. Ziegler D., Low P.A., Litchy W.J., et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011; 34 (9): 2054–60. DOI: https://doi.org/10.2337/dc11-0503
22. Grasso S., Bramanti V., Tomassoni D., et al. Effect of lipoic acid and glycerylphosphoryl-choline on astroglial cell proliferation and differentiation in primary culture. J Neurosci Res. 2014; 92 (1): 86–94. DOI: https://doi.org/10.1002/jnr.23289
23. Lee W.Y., Orestes P., Latham J., et al. Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway. J Neurosci. 2009; 29 (30): 9500–9. DOI: https://doi.org/10.1523/JNEUROSCI.5803-08.2009
24. Mijnhout G.S., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? Neth J Med. 2010; 68 (4): 158–62.
25. Dyck P.J., Albers J.W., Andersen H., et al.; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011; 27 (7): 620–8. DOI: https://doi.org/10.1002/dmrr.1226
26. Han T., Bai J., Liu W., Hu Y. A systematic review and meta-analysis of alpha-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012; 167 (4): 465–71. DOI: https://doi.org/10.1530/EJE-12-0555
27. Ziegler D., Nowak H., Kempler P., et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004; 21 (2): 114–21. DOI: https://doi.org/10.1111/j.1464-5491.2004.01109.x
28. Ziegler D., Tesfaye S., Spallone V., Gurieva I., Al Kaabi J., Mankovsky B., et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabetes Res Clin Pract. 2022; 186; 109063. DOI: https://doi.org/10.1016/j.diabres.2021.109063